Using Targeted Virotherapy to Treat a Resistant Ewing Sarcoma Model: From the Bedside to the Bench and Back

<table>VSVΔM51 infects multiple types of <i>ex-vivo</i> human sarcomas. Approximately 50% of the <i>ex-vivo</i> specimens tested are susceptible to VSVΔM51 infection.</table>

The Scientific World Journal

fig8

Figure 8

Figure 8: Using Targeted Virotherapy to Treat a Resistant Ewing Sarcoma Model: From the Bedside to the Bench and Back 